# OnCo record ascent-03 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ascent-03/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ascent-03", "NCT05382299" ;
  schema:name "ASCENT-03"@en ;
  schema:description "Moved Trodelvy into first-line use for triple-negative patients who cannot receive immunotherapy."@en ;
  schema:url <https://onco.cc/trials/ascent-03/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05382299>, <https://doi.org/10.1056/NEJMoa2511734>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TRODELVY%22> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2022-07-20" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ascent-03-n-engl-j-med-2025/> .